Urges NJ DOH to increase public awareness on effects of xylazine.
Impact
The resolution signifies a proactive measure to address a public health crisis stemming from the misuse of xylazine. It highlights xylazine's role as a central nervous system depressant that can lead to several severe health effects, including drowsiness, amnesia, and dangerously low heart rates and blood pressure. Given that xylazine is often mixed with other illicit drugs, particularly fentanyl, the NJ DOH is urged to take appropriate measures to educate the public on the dangers of this drug. This initiative may lead to increased funding and resources dedicated to drug awareness and prevention programs in New Jersey.
Summary
Assembly Resolution No. 82, introduced in New Jersey's 221st Legislature, urges the New Jersey Department of Health (NJ DOH) to enhance public awareness regarding the dangers associated with the drug xylazine, often referred to as 'Tranq' or 'Zombie Drug.' This resolution is significantly driven by growing concerns about its emergence as a street drug linked to an alarming increase in overdose deaths across New Jersey and neighboring states. The resolution highlights that xylazine is a non-opioid veterinary tranquilizer not approved for human use, which poses serious health risks when used recreationally.
Contention
Notably, the resolution underscores a significant gap in overdose response strategies, as naloxone, commonly used to counter opioid overdoses, is ineffective against xylazine. This limitation raises concerns among advocates for public health and safety, emphasizing the need for tailored educational approaches to address the unique risks posed by xylazine. The NJ DOH is thus called upon not only to increase awareness but also to develop educational materials specifically targeting the dangers associated with xylazine use, particularly in light of its rising prevalence in mixed drug use scenarios.